Labcorp: 3 Key Takeaways for Long-Term Investors
Tuck-in acquisitions and specialty testing momentum give Labcorp tools to offset a looming $125 million Medicare reimbursement hit.
Labcorp reported a 7% revenue growth to $3.8 billion for Q3 2026, while raising full-year earnings guidance. Management highlighted three key aspects for long-term investors: the impact of proposed fee schedule changes under the Protecting Access to Medicare Act (PAMA), high-growth specialty areas driving margins, and strategic acquisitions to boost market presence.
PAMA, set to take effect in 2027, will lower Medicare reimbursement rates for hundreds of tests, estimated to cause a $125 million hit. Labcorp plans to offset this by focusing on volume growth, biopharma demand, and cost efficiencies.
The specialty testing business, including oncology and neurology, is growing at about three times the rate of the broader diagnostics market. Physicians often order these specialized tests alongside other Labcorp services, creating a positive "halo effect" for the core laboratory business.
Strategic acquisitions of BioReference, Myriad Genetics' prenatal business, and Millennium Health are expected to be accretive to adjusted EPS in year one. These acquisitions help Labcorp maintain its strong global footprint, proprietary assay portfolio, and disciplined cost-saving initiatives through its Launchpad program.
Management emphasizes that operating efficiency, organic expansion, and pricing discipline are key drivers of long-term value creation. They remain confident in their strategy, particularly as regulatory policy shifts unfold, and highlight the company's position for continued strong performance.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
